parecoxib sold brand name dynastat among others watersoluble injectable prodrug valdecoxib parecoxib selective inhibitor injectable approved much europe short term perioperative pain control patented approved medical use us food drug administration fda issued letter nonapproval parecoxib united states reasons ever documented publicly nonapproval although one study noted increased occurrences heart attacks following cardiac bypass surgery compared placebo high doses parecoxib used control pain surgery importantly rare severe allergic reactions syndrome lyell syndrome described valdecoxib molecule parecoxib drug approved use cardiac surgery europe antiinflammatory medications us carry warning regarding skin reactions none approved use cabg surgery reason fda denying approval parecoxib remains unknown likely related political pressure us congress approve another selective inhibitor wake vioxx affair selective inhibitor approved us since time regardless safety profile parecoxib europe efforts find scientific rationale likely lack thereof fda used justify nonapproval parecoxib usa proven futile due secrecy political motivation approve parecoxib supported pooled analysis safety data published studies showed units parecoxib skin rash cardiac complications minimal different parecoxib along selective inhibitors celecoxib valdecoxib mavacoxib discovered team searle division monsanto led john parecoxib first parenteral selective inhibitor available clinical use pain management first perceptible analgesic effect occurs within seven thirteen minutes clinically meaningful analgesia demonstrated within twentythree thirtynine minutes peak effect within two hours following administration single doses mg iv im httpsenwikipediaorgwikiparecoxib